Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Structure-Activity Relationships of Novel Thiazole-Based Modafinil Analogues Acting at Monoamine Transporters.

Kalaba P, Ilić M, Aher NY, Dragačević V, Wieder M, Zehl M, Wackerlig J, Beyl S, Sartori SB, Ebner K, Roller A, Lukic N, Beryozkina T, Gonzalez ERP, Neill P, Khan JA, Bakulev V, Leban JJ, Hering S, Pifl C, Singewald N, Lubec J, Urban E, Sitte HH, Langer T, Lubec G.

J Med Chem. 2020 Jan 9;63(1):391-417. doi: 10.1021/acs.jmedchem.9b01938. Epub 2019 Dec 30.

PMID:
31841637
2.

Discovery of Inhibitor of Wnt Production 2 (IWP-2) and Related Compounds As Selective ATP-Competitive Inhibitors of Casein Kinase 1 (CK1) δ/ε.

García-Reyes B, Witt L, Jansen B, Karasu E, Gehring T, Leban J, Henne-Bruns D, Pichlo C, Brunstein E, Baumann U, Wesseler F, Rathmer B, Schade D, Peifer C, Knippschild U.

J Med Chem. 2018 May 10;61(9):4087-4102. doi: 10.1021/acs.jmedchem.8b00095. Epub 2018 May 1.

PMID:
29630366
3.

A daily single dose of a novel modafinil analogue CE-123 improves memory acquisition and memory retrieval.

Kristofova M, Aher YD, Ilic M, Radoman B, Kalaba P, Dragacevic V, Aher NY, Leban J, Korz V, Zanon L, Neuhaus W, Wieder M, Langer T, Urban E, Sitte HH, Hoeger H, Lubec G, Aradska J.

Behav Brain Res. 2018 May 2;343:83-94. doi: 10.1016/j.bbr.2018.01.032. Epub 2018 Feb 1.

PMID:
29410048
4.

Heterocyclic Analogues of Modafinil as Novel, Atypical Dopamine Transporter Inhibitors.

Kalaba P, Aher NY, Ilić M, Dragačević V, Wieder M, Miklosi AG, Zehl M, Wackerlig J, Roller A, Beryozkina T, Radoman B, Saroja SR, Lindner W, Gonzalez EP, Bakulev V, Leban JJ, Sitte HH, Urban E, Langer T, Lubec G.

J Med Chem. 2017 Nov 22;60(22):9330-9348. doi: 10.1021/acs.jmedchem.7b01313. Epub 2017 Nov 9.

PMID:
29091428
5.

A novel heterocyclic compound improves working memory in the radial arm maze and modulates the dopamine receptor D1R in frontal cortex of the Sprague-Dawley rat.

Hussein AM, Aher YD, Kalaba P, Aher NY, Dragačević V, Radoman B, Ilić M, Leban J, Beryozkina T, Ahmed ABMA, Urban E, Langer T, Lubec G.

Behav Brain Res. 2017 Aug 14;332:308-315. doi: 10.1016/j.bbr.2017.06.023. Epub 2017 Jun 16.

PMID:
28629964
6.

Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity.

Hutterer C, Milbradt J, Hamilton S, Zaja M, Leban J, Henry C, Vitt D, Steingruber M, Sonntag E, Zeitträger I, Bahsi H, Stamminger T, Rawlinson W, Strobl S, Marschall M.

Antiviral Res. 2017 Jul;143:113-121. doi: 10.1016/j.antiviral.2017.04.003. Epub 2017 Apr 9.

PMID:
28400201
7.

A novel heterocyclic compound targeting the dopamine transporter improves performance in the radial arm maze and modulates dopamine receptors D1-D3.

Saroja SR, Aher YD, Kalaba P, Aher NY, Zehl M, Korz V, Subramaniyan S, Miklosi AG, Zanon L, Neuhaus W, Höger H, Langer T, Urban E, Leban J, Lubec G.

Behav Brain Res. 2016 Oct 1;312:127-37. doi: 10.1016/j.bbr.2016.06.011. Epub 2016 Jun 8.

PMID:
27288589
8.

A Novel Heterocyclic Compound CE-104 Enhances Spatial Working Memory in the Radial Arm Maze in Rats and Modulates the Dopaminergic System.

Aher YD, Subramaniyan S, Shanmugasundaram B, Sase A, Saroja SR, Holy M, Höger H, Beryozkina T, Sitte HH, Leban JJ, Lubec G.

Front Behav Neurosci. 2016 Feb 22;10:20. doi: 10.3389/fnbeh.2016.00020. eCollection 2016.

9.

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.

Gruber W, Hutzinger M, Elmer DP, Parigger T, Sternberg C, Cegielkowski L, Zaja M, Leban J, Michel S, Hamm S, Vitt D, Aberger F.

Oncotarget. 2016 Feb 9;7(6):7134-48. doi: 10.18632/oncotarget.6910.

10.

A heterocyclic compound CE-103 inhibits dopamine reuptake and modulates dopamine transporter and dopamine D1-D3 containing receptor complexes.

Sase A, Aher YD, Saroja SR, Ganesan MK, Sase S, Holy M, Höger H, Bakulev V, Ecker GF, Langer T, Sitte HH, Leban J, Lubec G.

Neuropharmacology. 2016 Mar;102:186-96. doi: 10.1016/j.neuropharm.2015.07.039. Epub 2015 Sep 25.

PMID:
26407764
11.

The effect of modafinil on the rat dopamine transporter and dopamine receptors D1-D3 paralleling cognitive enhancement in the radial arm maze.

Karabacak Y, Sase S, Aher YD, Sase A, Saroja SR, Cicvaric A, Höger H, Berger M, Bakulev V, Sitte HH, Leban J, Monje FJ, Lubec G.

Front Behav Neurosci. 2015 Aug 19;9:215. doi: 10.3389/fnbeh.2015.00215. eCollection 2015.

12.

A new small molecule for treating inflammation and chorioretinal neovascularization in relapsing-remitting and chronic experimental autoimmune uveitis.

Diedrichs-Möhring M, Leban J, Strobl S, Obermayr F, Wildner G.

Invest Ophthalmol Vis Sci. 2014 Dec 16;56(2):1147-57. doi: 10.1167/iovs.14-15518.

PMID:
25515581
13.

Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients.

Richter J, Ullah K, Xu P, Alscher V, Blatz A, Peifer C, Halekotte J, Leban J, Vitt D, Holzmann K, Bakulev V, Pinna LA, Henne-Bruns D, Hillenbrand A, Kornmann M, Leithäuser F, Bischof J, Knippschild U.

Int J Cancer. 2015 Jun 15;136(12):2799-810. doi: 10.1002/ijc.29346. Epub 2014 Dec 1. Erratum in: Int J Cancer. 2016 Aug 15;139(4):E5.

14.

Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1δ and ε with nanomolar inhibitory activity on cancer cell proliferation.

Richter J, Bischof J, Zaja M, Kohlhof H, Othersen O, Vitt D, Alscher V, Pospiech I, García-Reyes B, Berg S, Leban J, Knippschild U.

J Med Chem. 2014 Oct 9;57(19):7933-46. doi: 10.1021/jm500600b. Epub 2014 Sep 17.

PMID:
25191940
15.

A novel DRAK inhibitor, SC82510, promotes axon branching of adult sensory neurons in vitro.

Marvaldi L, Hausott B, Auer M, Leban J, Klimaschewski L.

Neurochem Res. 2014 Feb;39(2):403-7. doi: 10.1007/s11064-014-1238-x. Epub 2014 Jan 10.

PMID:
24407843
16.

Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis.

Marschall M, Niemann I, Kosulin K, Bootz A, Wagner S, Dobner T, Herz T, Kramer B, Leban J, Vitt D, Stamminger T, Hutterer C, Strobl S.

Antiviral Res. 2013 Dec;100(3):640-8. doi: 10.1016/j.antiviral.2013.10.003. Epub 2013 Oct 20.

PMID:
24149002
17.

The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.

Haasbach E, Reiling SJ, Ehrhardt C, Droebner K, Rückle A, Hrincius ER, Leban J, Strobl S, Vitt D, Ludwig S, Planz O.

Antiviral Res. 2013 Sep;99(3):336-44. doi: 10.1016/j.antiviral.2013.06.008. Epub 2013 Jun 28.

PMID:
23811282
18.

The NF-κB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance.

Ehrhardt C, Rückle A, Hrincius ER, Haasbach E, Anhlan D, Ahmann K, Banning C, Reiling SJ, Kühn J, Strobl S, Vitt D, Leban J, Planz O, Ludwig S.

Cell Microbiol. 2013 Jul;15(7):1198-211. doi: 10.1111/cmi.12108. Epub 2013 Feb 5.

PMID:
23320394
19.

Immunosuppression with 4SC-101, a novel inhibitor of dihydroorotate dehydrogenase, in a rat model of renal transplantation.

Rusai K, Schmaderer C, Baumann M, Chmielewski S, Prókai A, Kis E, Szabó AJ, Leban J, Doblhofer R, Ammendola A, Lutz J, Heemann U.

Transplantation. 2012 Jun 15;93(11):1101-7. doi: 10.1097/TP.0b013e31824fd861.

PMID:
22609757
20.

Self condensation of enamines mediated by acetylation. A novel approach to 1-(azol-5-yl)-(1E,3Z)-butadiene-4-N,N-dimethylamines.

Shafran Y, Rozin Y, Beryozkina T, Zhidovinov S, Eltsov O, Subbotina J, Leban J, Novikova R, Bakulev V.

Org Biomol Chem. 2012 Aug 14;10(30):5795-8. doi: 10.1039/c2ob25331c. Epub 2012 Apr 17.

PMID:
22508270
21.

2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε.

Bischof J, Leban J, Zaja M, Grothey A, Radunsky B, Othersen O, Strobl S, Vitt D, Knippschild U.

Amino Acids. 2012 Oct;43(4):1577-91. Epub 2012 Feb 14.

22.

Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.

Leban J, Vitt D.

Arzneimittelforschung. 2011;61(1):66-72. doi: 10.1055/s-0031-1296169. Review.

PMID:
21355448
23.

4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.

Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ.

Am J Pathol. 2010 Jun;176(6):2840-7. doi: 10.2353/ajpath.2010.091227. Epub 2010 Apr 22.

24.

4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.

Fitzpatrick LR, Deml L, Hofmann C, Small JS, Groeppel M, Hamm S, Lemstra S, Leban J, Ammendola A.

Inflamm Bowel Dis. 2010 Oct;16(10):1763-77. doi: 10.1002/ibd.21264.

PMID:
20310011
25.

The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance.

Meinel FG, Mandl-Weber S, Baumann P, Leban J, Schmidmaier R.

Mol Cancer Ther. 2010 Feb;9(2):300-10. doi: 10.1158/1535-7163.MCT-09-0645. Epub 2010 Feb 2.

26.

SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.

Roth P, Kissel M, Herrmann C, Eisele G, Leban J, Weller M, Schmidt F.

Clin Cancer Res. 2009 Nov 1;15(21):6609-18. doi: 10.1158/1078-0432.CCR-09-0548. Epub 2009 Oct 13.

27.

X-ray microtomography studies of tannin-derived organic and carbon foams.

Tondi G, Blacher S, Léonard A, Pizzi A, Fierro V, Leban JM, Celzard A.

Microsc Microanal. 2009 Oct;15(5):384-94. doi: 10.1017/S1431927609990444. Epub 2009 Aug 27.

28.

The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.

Baumann P, Müller K, Mandl-Weber S, Leban J, Doblhofer R, Ammendola A, Baumgartner R, Oduncu F, Schmidmaier R.

Br J Haematol. 2009 Mar;144(6):875-86. doi: 10.1111/j.1365-2141.2008.07570.x. Epub 2009 Jan 16.

PMID:
19170678
29.

Proteasome inhibition by peptide-semicarbazones.

Leban J, Blisse M, Krauss B, Rath S, Baumgartner R, Seifert MH.

Bioorg Med Chem. 2008 Apr 15;16(8):4579-88. doi: 10.1016/j.bmc.2008.02.042. Epub 2008 Feb 15.

PMID:
18313310
30.

A novel class of potent NF-kappaB signaling inhibitors.

Leban J, Baierl M, Mies J, Trentinaglia V, Rath S, Kronthaler K, Wolf K, Gotschlich A, Seifert MH.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):5858-62. Epub 2007 Aug 15.

PMID:
17869512
31.

Dual binding mode of a novel series of DHODH inhibitors.

Baumgartner R, Walloschek M, Kralik M, Gotschlich A, Tasler S, Mies J, Leban J.

J Med Chem. 2006 Feb 23;49(4):1239-47.

PMID:
16480261
32.

Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors.

Leban J, Kralik M, Mies J, Baumgartner R, Gassen M, Tasler S.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):267-70. Epub 2005 Oct 21.

PMID:
16246558
33.

SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors.

Leban J, Kralik M, Mies J, Gassen M, Tentschert K, Baumgartner R.

Bioorg Med Chem Lett. 2005 Nov 1;15(21):4854-7.

PMID:
16143532
34.

Intra-annual variations in climate influence growth and wood density of Norway spruce.

Bouriaud O, Leban JM, Bert D, Deleuze C.

Tree Physiol. 2005 Jun;25(6):651-60.

PMID:
15805085
35.

Sulfonyl-phenyl-ureido benzamidines; a novel structural class of potent antimalarial agents.

Leban J, Pegoraro S, Dormeyer M, Lanzer M, Aschenbrenner A, Kramer B.

Bioorg Med Chem Lett. 2004 Apr 19;14(8):1979-82.

PMID:
15050641
36.

Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement.

Leban J, Saeb W, Garcia G, Baumgartner R, Kramer B.

Bioorg Med Chem Lett. 2004 Jan 5;14(1):55-8.

PMID:
14684297
37.

Hemodynamic characterization of a novel neuropeptide Y receptor antagonist.

Tadepalli AS, Harrington WW, Hashim MA, Matthews J, Leban JJ, Spaltenstein A, Daniels AJ.

J Cardiovasc Pharmacol. 1996 May;27(5):712-8.

PMID:
8859942
38.

Synthesis, structure and stability of novel dimeric peptide-disulfides.

Leban JJ, Spaltenstein A, Landavazo A, Chestnut W, Aulabaugh A, Taylor LC, Daniels AJ.

Int J Pept Protein Res. 1996 Mar;47(3):161-6.

PMID:
8740965
39.

BW 1023U90: a new GRP receptor antagonist for small-cell lung cancer cells.

Moody TW, Venugopal R, Hu V, Gozes Y, McDermed J, Leban JJ.

Peptides. 1996;17(8):1337-43.

PMID:
8971929
40.

High-affinity neuropeptide Y receptor antagonists.

Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A, Harrington W, Heyer D, Landavazo A, Leban JJ, Spaltenstein A.

Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9067-71.

41.
42.

Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release.

Furfine ES, Leban JJ, Landavazo A, Moomaw JF, Casey PJ.

Biochemistry. 1995 May 23;34(20):6857-62.

PMID:
7756316
43.

Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at a Y1-type receptor.

Leban JJ, Heyer D, Landavazo A, Matthews J, Aulabaugh A, Daniels AJ.

J Med Chem. 1995 Mar 31;38(7):1150-7.

PMID:
7707318
44.

BW2258U89: a GRP receptor antagonist which inhibits small cell lung cancer growth.

Moody TW, Venugopal R, Zia F, Patierno S, Leban JJ, McDermed J.

Life Sci. 1995;56(7):521-9.

PMID:
7869832
45.

A novel bombesin receptor antagonist selectively blocks the satiety action of peripherally administered bombesin.

Kirkham TC, Walsh CA, Gibbs J, Smith GP, Leban J, McDermed J.

Pharmacol Biochem Behav. 1994 Jul;48(3):809-11.

PMID:
7938140
46.

Potent gastrin-releasing peptide (GRP) antagonists derived from GRP (19-27) with a C-terminal DPro psi [CH2NH]Phe-NH2 and N-terminal aromatic residues.

Leban JJ, Landavazo A, McDermed JD, Diliberto EJ Jr, Jansen M, Stockstill B, Kull FC Jr.

J Med Chem. 1994 Feb 18;37(4):439-45.

PMID:
8120863
47.

Development of potent gastrin-releasing peptide antagonists having a D-Pro-psi(CH2NH)-Phe-NH2 C terminus.

Leban JJ, Kull FC Jr, Landavazo A, Stockstill B, McDermed JD.

Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1922-6.

48.

Conveyance of partial agonism/antagonism to bombesin/gastrin-releasing peptide analogues on Swiss 3T3 cells by a carboxyl-terminal leucine insertion.

Kull FC Jr, Leban JJ, Landavazo A, Stewart KD, Stockstill B, McDermed JD.

J Biol Chem. 1992 Oct 15;267(29):21132-8.

49.

Two-step binding mechanism for HIV protease inhibitors.

Furfine ES, D'Souza E, Ingold KJ, Leban JJ, Spector T, Porter DJ.

Biochemistry. 1992 Sep 1;31(34):7886-91.

PMID:
1510976

Supplemental Content

Support Center